Novel Platform: AVIDIO
(Artificial Virus for Infectious Diseases and Immuno-Oncology) Patented. Worldwide exclusive rights from Yale University
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.
Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University.